P482 Effects of pramipexole on periodic limb movements (PLMs) in restless legs syndrome (RLS): A polysomnographic study

Partinen, M; Hirvonen, Kari; Jama, Leni; Alakuijala, Anniina; Hublin, Christer; Tamminen, Ilkka; Koester, J.

doi:10.1016/j.sleep.2006.07.291

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 576 records were identified through database search, after we excluded two studies that used a self-control method before and after treatment, 43,44 two trials that did not include a washout period prior to the treatment, 45,46 one trial that used healthy volunteers as controls, 47 one trial that had a treatment duration less than seven days, 48 and nine repeated records, 49–57 twelve trials were ultimately included in our study. 20–31 …”

Section: Resultsmentioning

confidence: 99%

Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Liu

Wang

et al. 2016

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose The objective of this meta-analysis was to systematically evaluate the efficacy of pramipexole for the treatment of primary moderate to severe RLS. Methods Databases of PubMed, OVID, ScienceDirect, SpringerLink, Thomson Reuters Web of Science, the Cochrane Library, the Wiley Online Library, ArticleFirst, CALIS, Study, CNKI, and WanFang were searched to identify randomized controlled trials (RCTs) investigating pramipexole for the treatment of primary moderate to severe RLS. A meta-analysis was then conducted to pool results. Findings Twelve RCTs involving 3286 participants were included in this study. The average treatment duration was 11.12 (±5.72) weeks/person. The meta-analysis demonstrated that the post-treatment change in the International Restless Leg Syndrome Study Group Rating Scale (IRLS) score of pramipexole group was significantly superior to that of placebo group (weighted mean difference (WMD)=-4.64, 95% confidence intervals (CI) −5.95 to −3.33, n=8). More patients in pramipexole group showed at least a 50% reduction in the IRLS score after treatment (risk ratio [RR]) =1.57, 95% CI 1.43 to 1.73, n=8). In terms of the scores for the Clinical Global Impression of Improvement scale (CGI-I; RR=1.48, 95% CI 1.31 to 1.66, n=11) and the Patient Global Impression scale (PGI; RR=1.54, 95% CI 1.31 to 1.81, n=9), pramipexole group’s treatment outcomes were significantly superior to those of placebo group. In terms of the change in quality of life (WMD=5.39, 95% CI 2.28 to 8.50, n=4), change in daytime tiredness (WMD=-0.61, 95% CI −1.21 to −0.01, n=4), change in the number of periodic limb movements per hour of sleep (WMD=-35.95, 95% CI −56.42 to −15.48, n=3) and change in the quality of sleep (WMD=3.60, 95% CI 1.69 to 5.50, n=6), the treatment outcomes of pramipexole group were significantly superior to those of placebo group. Implications This meta-analysis study indicated that pramipexole could effectively improve the symptoms of primary moderate to severe RLS patients, although the quality of evidence was relatively low. Future clinical trials focusing on the medium-term and long-term treatment outcomes and using mainly objective indicators for evaluation are warranted. It is also necessary to pay close attention to augmentation during medication.

show abstract